[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617201":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":38,"locations":44,"responsibleParty":63,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":10,"maxAge":10,"enrollmentInfo":76,"targetDuration":79,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"St. Anne's University Hospital Brno, Czech Republic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with cartilaginous bone tumours",null,"The study cohort consists of patients with cartilaginous bone tumours treated at a tertiary orthopaedic oncology centre. This includes individuals with benign, borderline, and malignant chondroid lesions across the full biological spectrum, namely enchondromas, atypical cartilaginous tumours (ACT\u002FG1), conventional chondrosarcomas (grades G1-G3), dedifferentiated chondrosarcomas, and selected rare variants. Interventions of interest in this study are primarily diagnostic and molecular, rather than therapeutic in the interventional trial sense.\n\nMolecular analysis of tumour tissue using next-generation sequencing (NGS) to assess global microRNA expression profiles and IDH1\u002F2 mutation status.\n\nValidation of selected molecular markers using RT-qPCR and targeted mutation detection assays. Analysis of circulating and exosomal microRNAs from blood as a form of liquid biopsy. Experimental miRNA modulation to investigate biological relevance in relation to IDH1\u002F2 mutation status.",[13,14,15],"Diagnostic Test: Tumour tissue analysis","Diagnostic Test: Molecular validation","Diagnostic Test: Liquid biopsy analysis",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Tumour tissue analysis","Next-generation sequencing (NGS) to determine IDH1\u002F2 mutation status\n\nGlobal microRNA (miRNA) expression profiling using NGS",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"Molecular validation","Quantitative reverse transcription PCR (RT-qPCR) to validate selected miRNAs\n\nTargeted molecular assays for confirmation of IDH1\u002F2 mutations",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Liquid biopsy analysis","Assessment of circulating and exosomal miRNAs from patient body fluids as non-invasive biomarkers",[9],[31,35],{"name":32,"affiliation":33,"role":34},"Tomáš Tomáš, Assoc.Prof., M.D., Ph.D.","Faculty of Medicine, Masaryk University, Brno, 60200, Czechia","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":37,"role":34},"Michal Mahdal, M.D., Ph.D.","First Department of Orthopaedic Surgery, St. Anne's University Hospital, Brno, 60200, Czechia",[39],{"name":40,"role":41,"phone":42,"phoneExt":10,"email":43},"Vasileios Apostolopoulos, M.D., Ph.D.","CONTACT","+420722101065","vasileios.apostolopoulos@fnusa.cz",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":10,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia","RECRUITING","Brno","South Moravian","60200","Czechia",{"type":53,"coordinates":54},"Point",[55,56],16.60796,49.19522,{"lat":56,"lon":55},[59],{"name":60,"role":41,"phone":61,"phoneExt":10,"email":62},"Vasileios Apostolopoulos","722101065","Vasilis.apo@email.cz",{"type":64,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[66],{"name":67,"class":6},"Masaryk University","100617201","diagnostic-and-therapeutic-targets-in-cartilaginous-tumours-100617201",false,"NCT07315542","Diagnostic and Therapeutic Targets in Cartilaginous Tumours","Finding New Diagnostic and Therapeutic Targets in Cartilaginous Tumours","Inclusion Criteria\n\n* Histologically confirmed cartilaginous (chondroid) tumour\n* Diagnosis includes one of the following entities (as available and eligible):\n* Enchondroma\n* Atypical cartilaginous tumour \u002F Grade 1 chondrosarcoma (ACT\u002FG1)\n* Conventional chondrosarcoma (Grade 2-3)\n* Dedifferentiated chondrosarcoma\n* Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort\n* Patients treated and\u002For followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno\n\nExclusion Criteria\n\n* Insufficient, degraded, or otherwise unusable tissue samples","ALL",{"count":77,"type":78},300,"ESTIMATED","5 Years","OBSERVATIONAL","This study, \"Finding new diagnostic and therapeutic targets in cartilaginous tumours,\" focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma. Chondrosarcoma is the most common primary malignant bone tumour in adults and is characterized by resistance to chemotherapy and radiotherapy, making accurate diagnosis and optimal surgical management critical. Distinguishing benign cartilage tumours (enchondromas, atypical cartilaginous tumours) from low-grade chondrosarcoma, and differentiating chondrosarcoma from chondroblastic osteosarcoma, remain major diagnostic challenges.\n\nThe project investigates two key molecular markers: mutations in IDH1\u002F2 genes and non-coding microRNAs (miRNAs). IDH1\u002F2 mutations are frequent in central chondrosarcomas and rare in other mesenchymal tumours, making them promising diagnostic markers. Their presence may also have prognostic significance and therapeutic relevance, as IDH inhibitors are already available for other malignancies. In parallel, deregulated miRNA expression has been implicated in chondrosarcoma biology, influencing tumour growth, invasion, angiogenesis, metastasis, and chemosensitivity. Preliminary data identified distinct miRNA signatures in chondrosarcoma compared with healthy cartilage, including previously unreported miRNAs.\n\nThe study is structured into exploratory and validation phases. Global miRNA expression profiling and IDH1\u002F2 mutation analysis will be performed using next-generation sequencing (NGS) on prospectively collected fresh-frozen tumour samples. Selected miRNAs and IDH1\u002F2 mutation status will then be validated by RT-qPCR and targeted mutation assays in a large retrospective cohort of FFPE samples. Molecular data will be integrated with clinicopathological parameters to develop diagnostic panels capable of accurately classifying chondroid tumours, as well as prognostic miRNA panels associated with patient survival.\n\nAdditionally, the project evaluates circulating and exosomal miRNAs in liquid biopsies, aiming to establish non-invasive diagnostic and prognostic tools. Functional relevance will be explored using chondrosarcoma cell lines with simulated miRNA upregulation, coupled with transcriptomic analysis.\n\nOverall, the study seeks to refine diagnostic accuracy, improve prognostic assessment, and identify novel molecular targets for personalized and targeted therapy in patients with inoperable or metastatic chondrosarcoma, addressing a major unmet clinical need.",[83,84],"Chondrosarcomas","Cartilage Tumours",[86,87,88,89,90,91,92,93,94],"Chondrosarcoma","Liquid biopsy","Targeted therapy","Prognostic markers","Molecular biomarkers","MicroRNA (miRNA)","Cartilaginous tumours","IDH1 mutation","IDH2 mutation","2026-01-02",{"date":97,"type":98},"2026-01-05","ACTUAL",{"date":100,"type":98},"2025-05-01",{"date":102,"type":78},"2028-12-31",{"name":5,"class":6},1]